The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

Chih Chiang Chiu, Chun Hsin Chen, Bo Yu Chen, Shu Han Yu, Mong Liang Lu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The second generation antipsychotic drugs (SGAs) are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the time-dependent effects of olanzapine treatment on pancreatic beta cell function in SGA-naïve schizophrenic patients. Forty-two schizophrenic subjects received olanzapine therapy for 8. weeks and thirty-three of them completed the trial. Of whom 33 completers (21 male, mean ± SD age: 37.6 ± 8.0. years) were inpatients and unexposed to SGA. The metabolic parameters were quantitatively assessed at weeks 0, 2, 4, and 8 by the intravenous glucose tolerance test. After 56-day olanzapine treatment, subjects had significant increases in body weight and as well as in the levels of triglyceride, total cholesterol, and low-density lipoprotein. Insulin secretion significantly decreased at week 2, returned to baseline at week 4, and significantly increased at week 8. Of the total samples, 18.2% and 33.3% of them met the criteria for significant weight gain and metabolic syndrome after 8-week olanzapine treatment, respectively. This study indicates that olanzapine-treated schizophrenic patients displayed biphasic changes in insulin secretion to a hyperglycemic challenge. The results of this study support that olanzapine might directly influence pancreatic beta cell function.

Original languageEnglish
Pages (from-to)866-870
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume34
Issue number6
DOIs
Publication statusPublished - Aug 2010

Fingerprint

olanzapine
Insulin
Insulin-Secreting Cells
Antipsychotic Agents
Therapeutics
Glucose Tolerance Test
LDL Cholesterol
Weight Gain
Inpatients
Schizophrenia
Triglycerides
Body Weight

Keywords

  • Insulin resistance
  • Insulin secretion
  • Metabolic syndrome
  • Olanzapine
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology
  • Medicine(all)

Cite this

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. / Chiu, Chih Chiang; Chen, Chun Hsin; Chen, Bo Yu; Yu, Shu Han; Lu, Mong Liang.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 34, No. 6, 08.2010, p. 866-870.

Research output: Contribution to journalArticle

@article{6e41914e05614f1e9ab7df814aa095e5,
title = "The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine",
abstract = "The second generation antipsychotic drugs (SGAs) are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the time-dependent effects of olanzapine treatment on pancreatic beta cell function in SGA-na{\"i}ve schizophrenic patients. Forty-two schizophrenic subjects received olanzapine therapy for 8. weeks and thirty-three of them completed the trial. Of whom 33 completers (21 male, mean ± SD age: 37.6 ± 8.0. years) were inpatients and unexposed to SGA. The metabolic parameters were quantitatively assessed at weeks 0, 2, 4, and 8 by the intravenous glucose tolerance test. After 56-day olanzapine treatment, subjects had significant increases in body weight and as well as in the levels of triglyceride, total cholesterol, and low-density lipoprotein. Insulin secretion significantly decreased at week 2, returned to baseline at week 4, and significantly increased at week 8. Of the total samples, 18.2{\%} and 33.3{\%} of them met the criteria for significant weight gain and metabolic syndrome after 8-week olanzapine treatment, respectively. This study indicates that olanzapine-treated schizophrenic patients displayed biphasic changes in insulin secretion to a hyperglycemic challenge. The results of this study support that olanzapine might directly influence pancreatic beta cell function.",
keywords = "Insulin resistance, Insulin secretion, Metabolic syndrome, Olanzapine, Schizophrenia",
author = "Chiu, {Chih Chiang} and Chen, {Chun Hsin} and Chen, {Bo Yu} and Yu, {Shu Han} and Lu, {Mong Liang}",
year = "2010",
month = "8",
doi = "10.1016/j.pnpbp.2010.04.003",
language = "English",
volume = "34",
pages = "866--870",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

AU - Chiu, Chih Chiang

AU - Chen, Chun Hsin

AU - Chen, Bo Yu

AU - Yu, Shu Han

AU - Lu, Mong Liang

PY - 2010/8

Y1 - 2010/8

N2 - The second generation antipsychotic drugs (SGAs) are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the time-dependent effects of olanzapine treatment on pancreatic beta cell function in SGA-naïve schizophrenic patients. Forty-two schizophrenic subjects received olanzapine therapy for 8. weeks and thirty-three of them completed the trial. Of whom 33 completers (21 male, mean ± SD age: 37.6 ± 8.0. years) were inpatients and unexposed to SGA. The metabolic parameters were quantitatively assessed at weeks 0, 2, 4, and 8 by the intravenous glucose tolerance test. After 56-day olanzapine treatment, subjects had significant increases in body weight and as well as in the levels of triglyceride, total cholesterol, and low-density lipoprotein. Insulin secretion significantly decreased at week 2, returned to baseline at week 4, and significantly increased at week 8. Of the total samples, 18.2% and 33.3% of them met the criteria for significant weight gain and metabolic syndrome after 8-week olanzapine treatment, respectively. This study indicates that olanzapine-treated schizophrenic patients displayed biphasic changes in insulin secretion to a hyperglycemic challenge. The results of this study support that olanzapine might directly influence pancreatic beta cell function.

AB - The second generation antipsychotic drugs (SGAs) are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the time-dependent effects of olanzapine treatment on pancreatic beta cell function in SGA-naïve schizophrenic patients. Forty-two schizophrenic subjects received olanzapine therapy for 8. weeks and thirty-three of them completed the trial. Of whom 33 completers (21 male, mean ± SD age: 37.6 ± 8.0. years) were inpatients and unexposed to SGA. The metabolic parameters were quantitatively assessed at weeks 0, 2, 4, and 8 by the intravenous glucose tolerance test. After 56-day olanzapine treatment, subjects had significant increases in body weight and as well as in the levels of triglyceride, total cholesterol, and low-density lipoprotein. Insulin secretion significantly decreased at week 2, returned to baseline at week 4, and significantly increased at week 8. Of the total samples, 18.2% and 33.3% of them met the criteria for significant weight gain and metabolic syndrome after 8-week olanzapine treatment, respectively. This study indicates that olanzapine-treated schizophrenic patients displayed biphasic changes in insulin secretion to a hyperglycemic challenge. The results of this study support that olanzapine might directly influence pancreatic beta cell function.

KW - Insulin resistance

KW - Insulin secretion

KW - Metabolic syndrome

KW - Olanzapine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77955049395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955049395&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2010.04.003

DO - 10.1016/j.pnpbp.2010.04.003

M3 - Article

C2 - 20394794

AN - SCOPUS:77955049395

VL - 34

SP - 866

EP - 870

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 6

ER -